Cynata Therapeutics Limited (CYP.AX)
| Previous close | 0.5400 |
| Open | 0.5400 |
| Bid | 0.5200 x 1582700 |
| Ask | 0.5300 x 3535900 |
| Day's range | 0.5250 - 0.5500 |
| 52-week range | 0.4700 - 1.0868 |
| Volume | 73,133 |
| Avg. volume | 146,626 |
| Market cap | 75.22M |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0590 |
| Earnings date | 26 Aug 2021 - 27 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GlobeNewswire
Ethics Approval for Cynata’s Clinical Trial in Diabetic Foot Ulcers
Key highlights Ethics approval received for clinical trial in patients with diabetic foot ulcers First clinical trial to utilise the wound dressing technology recently licensed from TekCyte Patient recruitment expected to commence in 2H CY21 MELBOURNE, Australia, June 30, 2021 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received approval by th
- GlobeNewswire
Cynata signs Licence Agreement with TekCyte to advance Clinical Trial in Diabetic Foot Ulcers
MELBOURNE, Australia, June 03, 2021 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced the execution of a worldwide exclusive licence agreement with TekCyte Pty Ltd (TekCyte) in respect of TekCyte’s wound dressing technology. Cynata has also secured an option to purchase the relevant technology outright. Key highlights Secured worldwide exclusive licence agreement
